Are you over 18 and want to see adult content?
More Annotations
A complete backup of onlinestoreforu.com
Are you over 18 and want to see adult content?
A complete backup of inconvenienthistory.com
Are you over 18 and want to see adult content?
A complete backup of trumarkonline.org
Are you over 18 and want to see adult content?
A complete backup of thecanadianpress.com
Are you over 18 and want to see adult content?
A complete backup of magneticexchange.com
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of xdlatino.blogspot.com
Are you over 18 and want to see adult content?
Text
COVID BRAIN FOG
Akili digital therapeutic AKL-T01 was purposefully designed to improve cognitive impairments. We are working with leading academic researchers to study AKL-T01 as potential treatment for patients with COVID brain fog. Learn About COVID Brain Fog. Megan Ryll April 7, 2021. Discussion with leading academic researchers on COVID brain fog.PRODUCT DEVELOPMENT
Product Development We take breakthrough science from the lab to patients in the form of effective and captivating digital therapeutics. We uncover groundbreaking neuroscience from around the world and conduct internal discovery to develop new technologies withthe
DISCUSSION WITH LEADING ACADEMIC RESEARCHERS ON COVID Discussion with leading academic researchers on COVID brain fog. Akili is collaborating with Weill Cornell Medicine, NewYork-Presbyterian Hospital and Vanderbilt University Medical Center to study the potential of a digital therapeutic to treat brain fog in COVID-19 survivors. YouTube. Akili Interactive. 47 subscribers. ENDEAVORRX — AKILI INTERACTIVE EndeavorRx® is the first-and-only FDA cleared prescription treatment for attention in children with ADHD delivered through a digitaltherapy.
GET ENDEAVOR
Scroll. EndeavorRx® is the first-and-only FDA cleared prescription treatment for attention in children with ADHD delivered through a digital therapy. If you'd like to be informed of updates to EndeavorRx, please fill out the form below. * required field. By submitting this form, you consent to Akili processing your data or personal information AKILI ANNOUNCES FDA CLEARANCE OF ENDEAVORRX™ FOR CHILDREN Shown to improve attention function, EndeavorRx is backed by data from five clinical studies , including a prospective, randomized controlled trial BOSTON, Mass – June 15, 2020 – Akili today announce d that the U.S. Food and Drug AdministratJACQUELINE STUDER
Jacqueline Studer. Senior Vice President and General Counsel. Ms. Studer comes to Akili with a 20+ year track record as a senior legal executive building, growing and leading transformative technology companies in highly regulated sectors. Prior to joining Akili, Ms. Studer led the legal, compliance and regulatory organizations asCorporate
AKILI INTERACTIVEPRODUCTSWHO WE AREJOIN USNEWSCONTACTMATTHEW OMERNICK Akili Interactive is a prescription digital medicine company combining scientific and clinical rigor with the ingenuity of the tech industry to reinvent medicine. PRODUCTS — AKILI INTERACTIVE STARS-Adjunct: Akili data on file, NCT03649074 (manuscript in progress) Of 538 participants using EndeavorRx in clinical studies, 50 participants (9.3%) experienced treatment-related adverse events including frustration, headache, dizziness, emotional reaction, nausea, and aggression. There were no serious adverse events reported. WHO WE ARE — AKILI INTERACTIVE All of us at Akili (affectionately known as Akilians), are committed to challenging the status quo of medicine to help people living with cognitive impairment. We are passionate about bringing together top science and entertainment with great user experience to forever change how medicine is designed and delivered. Our Leadership. Featured.COVID BRAIN FOG
Akili digital therapeutic AKL-T01 was purposefully designed to improve cognitive impairments. We are working with leading academic researchers to study AKL-T01 as potential treatment for patients with COVID brain fog. Learn About COVID Brain Fog. Megan Ryll April 7, 2021. Discussion with leading academic researchers on COVID brain fog.PRODUCT DEVELOPMENT
Product Development We take breakthrough science from the lab to patients in the form of effective and captivating digital therapeutics. We uncover groundbreaking neuroscience from around the world and conduct internal discovery to develop new technologies withthe
DISCUSSION WITH LEADING ACADEMIC RESEARCHERS ON COVID Discussion with leading academic researchers on COVID brain fog. Akili is collaborating with Weill Cornell Medicine, NewYork-Presbyterian Hospital and Vanderbilt University Medical Center to study the potential of a digital therapeutic to treat brain fog in COVID-19 survivors. YouTube. Akili Interactive. 47 subscribers. ENDEAVORRX — AKILI INTERACTIVE EndeavorRx® is the first-and-only FDA cleared prescription treatment for attention in children with ADHD delivered through a digitaltherapy.
GET ENDEAVOR
Scroll. EndeavorRx® is the first-and-only FDA cleared prescription treatment for attention in children with ADHD delivered through a digital therapy. If you'd like to be informed of updates to EndeavorRx, please fill out the form below. * required field. By submitting this form, you consent to Akili processing your data or personal information AKILI ANNOUNCES FDA CLEARANCE OF ENDEAVORRX™ FOR CHILDREN Shown to improve attention function, EndeavorRx is backed by data from five clinical studies , including a prospective, randomized controlled trial BOSTON, Mass – June 15, 2020 – Akili today announce d that the U.S. Food and Drug AdministratJACQUELINE STUDER
Jacqueline Studer. Senior Vice President and General Counsel. Ms. Studer comes to Akili with a 20+ year track record as a senior legal executive building, growing and leading transformative technology companies in highly regulated sectors. Prior to joining Akili, Ms. Studer led the legal, compliance and regulatory organizations asCorporate
COVID BRAIN FOG
Research Spotlight: COVID Brain Fog More than 100 million people across the globe have been infected with COVID-19. Evidence is mounting on long-term neurological and cognitive symptoms that can persist in some COVID-19 patients, including after the virus is no longer detected in the body.PRODUCT DEVELOPMENT
Product Development We take breakthrough science from the lab to patients in the form of effective and captivating digital therapeutics. We uncover groundbreaking neuroscience from around the world and conduct internal discovery to develop new technologies withthe
PUBLICATIONS
Publications. Neurodevelopmental disorders: Attention Deficit/Hyperactivity Disorder (ADHD), Autism Spectrum Disorder (ASD) and Sensory Processing Disorder (SPD) Open label study in children with ADHD, both on and off medications: Published in npj Digital Medicin e on March 26, 2021. Kollins, S.H., Childress, A, Heusser, AC and Lutz, J. (2021). SCIENCE & TECHNOLOGY Explore the science and technology behind our digital treatments. Developed through the collaboration of world-renowned cognitive neuroscientists and acclaimed entertainment and technology designers, Akili has created a proprietary technology platform that represents an entirely new category of medicine.GET ENDEAVOR
Scroll. EndeavorRx® is the first-and-only FDA cleared prescription treatment for attention in children with ADHD delivered through a digital therapy. If you'd like to be informed of updates to EndeavorRx, please fill out the form below. * required field. By submitting this form, you consent to Akili processing your data or personal information LEARN ABOUT COVID BRAIN FOG Science & Tech Overview Product Development COVID Brain Fog Publications Products. Who We Are Join Us News Contact. Learn About COVID Brain Fog. Megan Ryll April 7, 2021. Facebook 0 Twitter Pinterest 0 0 Likes. Next. Discussion with leading academic researchers on COVID brain fog. CONTACT — AKILI INTERACTIVE Boston Office. 125 Broad Street. 5th Floor. Boston, MA 02110. SF Bay Area Office. 125 E Sir Francis Drake Blvd. Suite 300. Larkspur, CA94939.
AKILI ANNOUNCES APPOINTMENT OF CHIEF MARKETING OFFICER Meghan Rivera Brings Strong Track Record of Award-winning Disruptive Healthcare Launch Experience. BOSTON, Mass – October 7, 2020 – Akili today announced the expansion of the company’s executive team with the appointment of Meghan Rivera to the role of Chief Marketing Officer. In the newly created position, Rivera will lead marketing and sales of EndeavorRx, the company’s firstEDDIE MARTUCCI
Eddie Martucci, PhD. Co-Founder - Chief Executive Officer. Eddie co-founded Akili Interactive Labs, and as part of PureTech has co-founded two other health-focused start-ups, and helped launch their digital health initiative. He was previously a Kauffman Entrepreneur Fellow, a program sponsored by the Kauffman Foundation of Kansas City,MO
ROB PEREZ — AKILI INTERACTIVE Rob Perez. Executive Chairman & Board Member. Rob Perez is a biopharmaceutical operating executive with more than 25 years of experience in the industry. He is currently the founder and Managing Partner of Vineyard Sound Advisors, LLC as well as the founder and Chairman of Life Science Cares. Previously, he was the Chief ExecutiveOfficer of
AKILI INTERACTIVEPRODUCTSWHO WE AREJOIN USNEWSCONTACTMATTHEW OMERNICK Akili Interactive is a prescription digital medicine company combining scientific and clinical rigor with the ingenuity of the tech industry to reinvent medicine. PRODUCTS — AKILI INTERACTIVE STARS-Adjunct: Akili data on file, NCT03649074 (manuscript in progress) Of 538 participants using EndeavorRx in clinical studies, 50 participants (9.3%) experienced treatment-related adverse events including frustration, headache, dizziness, emotional reaction, nausea, and aggression. There were no serious adverse events reported. WHO WE ARE — AKILI INTERACTIVE All of us at Akili (affectionately known as Akilians), are committed to challenging the status quo of medicine to help people living with cognitive impairment. We are passionate about bringing together top science and entertainment with great user experience to forever change how medicine is designed and delivered. Our Leadership. Featured.PRODUCT DEVELOPMENT
Product Development We take breakthrough science from the lab to patients in the form of effective and captivating digital therapeutics. We uncover groundbreaking neuroscience from around the world and conduct internal discovery to develop new technologies withthe
DISCUSSION WITH LEADING ACADEMIC RESEARCHERS ON COVID Discussion with leading academic researchers on COVID brain fog. Akili is collaborating with Weill Cornell Medicine, NewYork-Presbyterian Hospital and Vanderbilt University Medical Center to study the potential of a digital therapeutic to treat brain fog in COVID-19 survivors. YouTube. Akili Interactive. 47 subscribers. ENDEAVORRX — AKILI INTERACTIVE EndeavorRx® is the first-and-only FDA cleared prescription treatment for attention in children with ADHD delivered through a digitaltherapy.
GET ENDEAVOR
Scroll. EndeavorRx® is the first-and-only FDA cleared prescription treatment for attention in children with ADHD delivered through a digital therapy. If you'd like to be informed of updates to EndeavorRx, please fill out the form below. * required field. By submitting this form, you consent to Akili processing your data or personal information AKILI ANNOUNCES PUBLICATION OF AKL-T01 ADHD PIVOTAL STUDY First publication of complete results shows improvement across both objective measures of attention and parent and clinician ratings of ADHD symptoms and functional impairments Study results suggest AKL-T01 could play an important role in the AKILI TECHNOLOGY IMPROVES COGNITIVE IMPAIRMENTS IN ADULTS Primary Endpoint Achieved in Randomized, Controlled Trial of Digital Therapeutic AKL-T03 in Major Depressive Disorder (MDD). Data Presented at the 58 th Annual Meeting of the American College of Neuropsychopharmacology. BOSTON, Mass – December 12, 2019 – Akili Interactive (“Akili” or “Company"), today announced results of its randomized, controlled study of digital therapeutic AKLJACQUELINE STUDER
Jacqueline Studer. Senior Vice President and General Counsel. Ms. Studer comes to Akili with a 20+ year track record as a senior legal executive building, growing and leading transformative technology companies in highly regulated sectors. Prior to joining Akili, Ms. Studer led the legal, compliance and regulatory organizations asCorporate
AKILI INTERACTIVEPRODUCTSWHO WE AREJOIN USNEWSCONTACTMATTHEW OMERNICK Akili Interactive is a prescription digital medicine company combining scientific and clinical rigor with the ingenuity of the tech industry to reinvent medicine. PRODUCTS — AKILI INTERACTIVE STARS-Adjunct: Akili data on file, NCT03649074 (manuscript in progress) Of 538 participants using EndeavorRx in clinical studies, 50 participants (9.3%) experienced treatment-related adverse events including frustration, headache, dizziness, emotional reaction, nausea, and aggression. There were no serious adverse events reported. WHO WE ARE — AKILI INTERACTIVE All of us at Akili (affectionately known as Akilians), are committed to challenging the status quo of medicine to help people living with cognitive impairment. We are passionate about bringing together top science and entertainment with great user experience to forever change how medicine is designed and delivered. Our Leadership. Featured.PRODUCT DEVELOPMENT
Product Development We take breakthrough science from the lab to patients in the form of effective and captivating digital therapeutics. We uncover groundbreaking neuroscience from around the world and conduct internal discovery to develop new technologies withthe
DISCUSSION WITH LEADING ACADEMIC RESEARCHERS ON COVID Discussion with leading academic researchers on COVID brain fog. Akili is collaborating with Weill Cornell Medicine, NewYork-Presbyterian Hospital and Vanderbilt University Medical Center to study the potential of a digital therapeutic to treat brain fog in COVID-19 survivors. YouTube. Akili Interactive. 47 subscribers. ENDEAVORRX — AKILI INTERACTIVE EndeavorRx® is the first-and-only FDA cleared prescription treatment for attention in children with ADHD delivered through a digitaltherapy.
GET ENDEAVOR
Scroll. EndeavorRx® is the first-and-only FDA cleared prescription treatment for attention in children with ADHD delivered through a digital therapy. If you'd like to be informed of updates to EndeavorRx, please fill out the form below. * required field. By submitting this form, you consent to Akili processing your data or personal information AKILI ANNOUNCES PUBLICATION OF AKL-T01 ADHD PIVOTAL STUDY First publication of complete results shows improvement across both objective measures of attention and parent and clinician ratings of ADHD symptoms and functional impairments Study results suggest AKL-T01 could play an important role in the AKILI TECHNOLOGY IMPROVES COGNITIVE IMPAIRMENTS IN ADULTS Primary Endpoint Achieved in Randomized, Controlled Trial of Digital Therapeutic AKL-T03 in Major Depressive Disorder (MDD). Data Presented at the 58 th Annual Meeting of the American College of Neuropsychopharmacology. BOSTON, Mass – December 12, 2019 – Akili Interactive (“Akili” or “Company"), today announced results of its randomized, controlled study of digital therapeutic AKLJACQUELINE STUDER
Jacqueline Studer. Senior Vice President and General Counsel. Ms. Studer comes to Akili with a 20+ year track record as a senior legal executive building, growing and leading transformative technology companies in highly regulated sectors. Prior to joining Akili, Ms. Studer led the legal, compliance and regulatory organizations asCorporate
PRODUCTS — AKILI INTERACTIVE STARS-Adjunct: Akili data on file, NCT03649074 (manuscript in progress) Of 538 participants using EndeavorRx in clinical studies, 50 participants (9.3%) experienced treatment-related adverse events including frustration, headache, dizziness, emotional reaction, nausea, and aggression. There were no serious adverse events reported. NEWS — AKILI INTERACTIVE Explore the latest news from Akili. For press inquiries, please contact pr@akiliinteractive.com. Featured. Apr 7, 2021. Akili Collaborates with Weill Cornell Medicine, NewYork-Presbyterian Hospital and Vanderbilt University Medical Center to Study Digital Therapeutic AKL-T01 as Treatment for COVID Brain Fog. Apr 7, 2021. Read More →. Apr 7, 2021.PUBLICATIONS
Publications. Neurodevelopmental disorders: Attention Deficit/Hyperactivity Disorder (ADHD), Autism Spectrum Disorder (ASD) and Sensory Processing Disorder (SPD) Open label study in children with ADHD, both on and off medications: Published in npj Digital Medicin e on March 26, 2021. Kollins, S.H., Childress, A, Heusser, AC and Lutz, J. (2021).PRODUCT DEVELOPMENT
Product Development We take breakthrough science from the lab to patients in the form of effective and captivating digital therapeutics. We uncover groundbreaking neuroscience from around the world and conduct internal discovery to develop new technologies withthe
JOBS — AKILI INTERACTIVE Science & Tech Products Who We Are Join Us News Contact Back Overview Product Development COVID Brain Fog Publications SCIENCE & TECHNOLOGY Explore the science and technology behind our digital treatments. Developed through the collaboration of world-renowned cognitive neuroscientists and acclaimed entertainment and technology designers, Akili has created a proprietary technology platform that represents an entirely new category of medicine. AKILI SECURES $160 MILLION IN FINANCING; POISED TO DELIVER Funding will accelerate commercialization of Akili’s flagship treatment EndeavorRx™, enable expansion of Akili’s core technology to treat acute and chronic cognitive disorders, and drive further research and development of new technologies to treat broader range ofconditions
EDDIE MARTUCCI
Eddie Martucci, PhD. Co-Founder - Chief Executive Officer. Eddie co-founded Akili Interactive Labs, and as part of PureTech has co-founded two other health-focused start-ups, and helped launch their digital health initiative. He was previously a Kauffman Entrepreneur Fellow, a program sponsored by the Kauffman Foundation of Kansas City,MO
ANIL JINA — AKILI INTERACTIVE Anil Jina. Chief Medical Officer. Dr. Jina studied medicine in Ireland at RCSI (the Royal College of Surgeons in Ireland) and worked as a hospital physician in the Irish healthcare system until he joined the biopharmaceutical industry in 2001. He has worked with Pfizer (CNS Medical Adviser, UK/Ireland and Global Medical Director, Psychiatry AKILI ANNOUNCES EXCLUSIVE LICENSING AGREEMENT FOR NEW BOSTON, Mass – August 9, 2018 – BOSTON--(BUSINESS WIRE)--Akili Interactive (“Akili” or “Company"), a leading prescription digital medicine company developing novel treatments for cognitive dysfunction and brain-related conditions, today announced an agreement with the Regents of the University of California to exclusively license new digital technology integrating neural systems that AKILI INTERACTIVEPRODUCTSWHO WE AREJOIN USNEWSCONTACTMATTHEW OMERNICK Akili Interactive is a prescription digital medicine company combining scientific and clinical rigor with the ingenuity of the tech industry to reinvent medicine. PRODUCTS — AKILI INTERACTIVE STARS-Adjunct: Akili data on file, NCT03649074 (manuscript in progress) Of 538 participants using EndeavorRx in clinical studies, 50 participants (9.3%) experienced treatment-related adverse events including frustration, headache, dizziness, emotional reaction, nausea, and aggression. There were no serious adverse events reported.COVID BRAIN FOG
Akili digital therapeutic AKL-T01 was purposefully designed to improve cognitive impairments. We are working with leading academic researchers to study AKL-T01 as potential treatment for patients with COVID brain fog. Learn About COVID Brain Fog. Megan Ryll April 7, 2021. Discussion with leading academic researchers on COVID brain fog. ENDEAVORRX — AKILI INTERACTIVE EndeavorRx® is the first-and-only FDA cleared prescription treatment for attention in children with ADHD delivered through a digitaltherapy.
PRODUCT DEVELOPMENT
Product Development We take breakthrough science from the lab to patients in the form of effective and captivating digital therapeutics. We uncover groundbreaking neuroscience from around the world and conduct internal discovery to develop new technologies withthe
DISCUSSION WITH LEADING ACADEMIC RESEARCHERS ON COVID Discussion with leading academic researchers on COVID brain fog. Akili is collaborating with Weill Cornell Medicine, NewYork-Presbyterian Hospital and Vanderbilt University Medical Center to study the potential of a digital therapeutic to treat brain fog in COVID-19 survivors. YouTube. Akili Interactive. 47 subscribers. SCIENCE & TECHNOLOGY Explore the science and technology behind our digital treatments. Developed through the collaboration of world-renowned cognitive neuroscientists and acclaimed entertainment and technology designers, Akili has created a proprietary technology platform that represents an entirely new category of medicine. AKILI TECHNOLOGY IMPROVES COGNITIVE IMPAIRMENTS IN ADULTS Primary Endpoint Achieved in Randomized, Controlled Trial of Digital Therapeutic AKL-T03 in Major Depressive Disorder (MDD). Data Presented at the 58 th Annual Meeting of the American College of Neuropsychopharmacology. BOSTON, Mass – December 12, 2019 – Akili Interactive (“Akili” or “Company"), today announced results of its randomized, controlled study of digital therapeutic AKL AKILI ANNOUNCES PUBLICATION OF AKL-T01 ADHD PIVOTAL STUDY First publication of complete results shows improvement across both objective measures of attention and parent and clinician ratings of ADHD symptoms and functional impairments Study results suggest AKL-T01 could play an important role in theJACQUELINE STUDER
Jacqueline Studer. Senior Vice President and General Counsel. Ms. Studer comes to Akili with a 20+ year track record as a senior legal executive building, growing and leading transformative technology companies in highly regulated sectors. Prior to joining Akili, Ms. Studer led the legal, compliance and regulatory organizations asCorporate
AKILI INTERACTIVEPRODUCTSWHO WE AREJOIN USNEWSCONTACTMATTHEW OMERNICK Akili Interactive is a prescription digital medicine company combining scientific and clinical rigor with the ingenuity of the tech industry to reinvent medicine. PRODUCTS — AKILI INTERACTIVE STARS-Adjunct: Akili data on file, NCT03649074 (manuscript in progress) Of 538 participants using EndeavorRx in clinical studies, 50 participants (9.3%) experienced treatment-related adverse events including frustration, headache, dizziness, emotional reaction, nausea, and aggression. There were no serious adverse events reported.COVID BRAIN FOG
Akili digital therapeutic AKL-T01 was purposefully designed to improve cognitive impairments. We are working with leading academic researchers to study AKL-T01 as potential treatment for patients with COVID brain fog. Learn About COVID Brain Fog. Megan Ryll April 7, 2021. Discussion with leading academic researchers on COVID brain fog. ENDEAVORRX — AKILI INTERACTIVE EndeavorRx® is the first-and-only FDA cleared prescription treatment for attention in children with ADHD delivered through a digitaltherapy.
PRODUCT DEVELOPMENT
Product Development We take breakthrough science from the lab to patients in the form of effective and captivating digital therapeutics. We uncover groundbreaking neuroscience from around the world and conduct internal discovery to develop new technologies withthe
DISCUSSION WITH LEADING ACADEMIC RESEARCHERS ON COVID Discussion with leading academic researchers on COVID brain fog. Akili is collaborating with Weill Cornell Medicine, NewYork-Presbyterian Hospital and Vanderbilt University Medical Center to study the potential of a digital therapeutic to treat brain fog in COVID-19 survivors. YouTube. Akili Interactive. 47 subscribers. SCIENCE & TECHNOLOGY Explore the science and technology behind our digital treatments. Developed through the collaboration of world-renowned cognitive neuroscientists and acclaimed entertainment and technology designers, Akili has created a proprietary technology platform that represents an entirely new category of medicine. AKILI TECHNOLOGY IMPROVES COGNITIVE IMPAIRMENTS IN ADULTS Primary Endpoint Achieved in Randomized, Controlled Trial of Digital Therapeutic AKL-T03 in Major Depressive Disorder (MDD). Data Presented at the 58 th Annual Meeting of the American College of Neuropsychopharmacology. BOSTON, Mass – December 12, 2019 – Akili Interactive (“Akili” or “Company"), today announced results of its randomized, controlled study of digital therapeutic AKL AKILI ANNOUNCES PUBLICATION OF AKL-T01 ADHD PIVOTAL STUDY First publication of complete results shows improvement across both objective measures of attention and parent and clinician ratings of ADHD symptoms and functional impairments Study results suggest AKL-T01 could play an important role in theJACQUELINE STUDER
Jacqueline Studer. Senior Vice President and General Counsel. Ms. Studer comes to Akili with a 20+ year track record as a senior legal executive building, growing and leading transformative technology companies in highly regulated sectors. Prior to joining Akili, Ms. Studer led the legal, compliance and regulatory organizations asCorporate
WHO WE ARE — AKILI INTERACTIVE All of us at Akili (affectionately known as Akilians), are committed to challenging the status quo of medicine to help people living with cognitive impairment. We are passionate about bringing together top science and entertainment with great user experience to forever change how medicine is designed and delivered. Our Leadership. Featured.PRODUCT DEVELOPMENT
Product Development We take breakthrough science from the lab to patients in the form of effective and captivating digital therapeutics. We uncover groundbreaking neuroscience from around the world and conduct internal discovery to develop new technologies withthe
PUBLICATIONS
Publications. Neurodevelopmental disorders: Attention Deficit/Hyperactivity Disorder (ADHD), Autism Spectrum Disorder (ASD) and Sensory Processing Disorder (SPD) Open label study in children with ADHD, both on and off medications: Published in npj Digital Medicin e on March 26, 2021. Kollins, S.H., Childress, A, Heusser, AC and Lutz, J. (2021).COVID BRAIN FOG
Research Spotlight: COVID Brain Fog More than 100 million people across the globe have been infected with COVID-19. Evidence is mounting on long-term neurological and cognitive symptoms that can persist in some COVID-19 patients, including after the virus is no longer detected in the body.GET ENDEAVOR
Scroll. EndeavorRx® is the first-and-only FDA cleared prescription treatment for attention in children with ADHD delivered through a digital therapy. If you'd like to be informed of updates to EndeavorRx, please fill out the form below. * required field. By submitting this form, you consent to Akili processing your data or personal information JOIN US — AKILI INTERACTIVE Join Us — Akili Interactive. Scroll. Help us change the way medicine is designed, delivered, and experienced. At Akili Interactive, our mission is to ignite new hope for those living with cognitive impairment. We’re bringing together world-class neuroscience with the latest technology and video game entertainment to create a newclass of
SUPPORTERS GALLERY
Ladera Venture Partners (LVP) is a Silicon Valley-based investment firm focused on investments at the convergence of technology and health. LVP is stage-agnostic and highly nimble, focusing on opportunities where the firm's experience, networks and insight can provide meaningful incremental value. Core focus areas include virtualcare, mental
ROB PEREZ — AKILI INTERACTIVE Rob Perez. Executive Chairman & Board Member. Rob Perez is a biopharmaceutical operating executive with more than 25 years of experience in the industry. He is currently the founder and Managing Partner of Vineyard Sound Advisors, LLC as well as the founder and Chairman of Life Science Cares. Previously, he was the Chief ExecutiveOfficer of
EDDIE MARTUCCI
Eddie Martucci, PhD. Co-Founder - Chief Executive Officer. Eddie co-founded Akili Interactive Labs, and as part of PureTech has co-founded two other health-focused start-ups, and helped launch their digital health initiative. He was previously a Kauffman Entrepreneur Fellow, a program sponsored by the Kauffman Foundation of Kansas City,MO
MATTHEW OMERNICK
Matthew Omernick. Co-Founder - Chief Creative Officer. Matt was most recently Executive Art Director at LucasArts, the video game division of Lucasfilm. Matt oversaw studio-wide art teams on multiple projects. Prior to LucasArts, he held Senior positions at Microsoft, Dreamworks, Electronic Arts, and Day 1 Studios. Matt has shipped over 20 game AKILI INTERACTIVEPRODUCTSWHO WE AREJOIN USNEWSCONTACTMATTHEW OMERNICK Akili Interactive is a prescription digital medicine company combining scientific and clinical rigor with the ingenuity of the tech industry to reinvent medicine. PRODUCTS — AKILI INTERACTIVE STARS-Adjunct: Akili data on file, NCT03649074 (manuscript in progress) Of 538 participants using EndeavorRx in clinical studies, 50 participants (9.3%) experienced treatment-related adverse events including frustration, headache, dizziness, emotional reaction, nausea, and aggression. There were no serious adverse events reported.COVID BRAIN FOG
Akili digital therapeutic AKL-T01 was purposefully designed to improve cognitive impairments. We are working with leading academic researchers to study AKL-T01 as potential treatment for patients with COVID brain fog. Learn About COVID Brain Fog. Megan Ryll April 7, 2021. Discussion with leading academic researchers on COVID brain fog. ENDEAVORRX — AKILI INTERACTIVE EndeavorRx® is the first-and-only FDA cleared prescription treatment for attention in children with ADHD delivered through a digitaltherapy.
PRODUCT DEVELOPMENT
Product Development We take breakthrough science from the lab to patients in the form of effective and captivating digital therapeutics. We uncover groundbreaking neuroscience from around the world and conduct internal discovery to develop new technologies withthe
DISCUSSION WITH LEADING ACADEMIC RESEARCHERS ON COVID Discussion with leading academic researchers on COVID brain fog. Akili is collaborating with Weill Cornell Medicine, NewYork-Presbyterian Hospital and Vanderbilt University Medical Center to study the potential of a digital therapeutic to treat brain fog in COVID-19 survivors. YouTube. Akili Interactive. 47 subscribers. SCIENCE & TECHNOLOGY Explore the science and technology behind our digital treatments. Developed through the collaboration of world-renowned cognitive neuroscientists and acclaimed entertainment and technology designers, Akili has created a proprietary technology platform that represents an entirely new category of medicine. AKILI TECHNOLOGY IMPROVES COGNITIVE IMPAIRMENTS IN ADULTS Primary Endpoint Achieved in Randomized, Controlled Trial of Digital Therapeutic AKL-T03 in Major Depressive Disorder (MDD). Data Presented at the 58 th Annual Meeting of the American College of Neuropsychopharmacology. BOSTON, Mass – December 12, 2019 – Akili Interactive (“Akili” or “Company"), today announced results of its randomized, controlled study of digital therapeutic AKL AKILI ANNOUNCES PUBLICATION OF AKL-T01 ADHD PIVOTAL STUDY First publication of complete results shows improvement across both objective measures of attention and parent and clinician ratings of ADHD symptoms and functional impairments Study results suggest AKL-T01 could play an important role in theJACQUELINE STUDER
Jacqueline Studer. Senior Vice President and General Counsel. Ms. Studer comes to Akili with a 20+ year track record as a senior legal executive building, growing and leading transformative technology companies in highly regulated sectors. Prior to joining Akili, Ms. Studer led the legal, compliance and regulatory organizations asCorporate
AKILI INTERACTIVEPRODUCTSWHO WE AREJOIN USNEWSCONTACTMATTHEW OMERNICK Akili Interactive is a prescription digital medicine company combining scientific and clinical rigor with the ingenuity of the tech industry to reinvent medicine. PRODUCTS — AKILI INTERACTIVE STARS-Adjunct: Akili data on file, NCT03649074 (manuscript in progress) Of 538 participants using EndeavorRx in clinical studies, 50 participants (9.3%) experienced treatment-related adverse events including frustration, headache, dizziness, emotional reaction, nausea, and aggression. There were no serious adverse events reported.COVID BRAIN FOG
Akili digital therapeutic AKL-T01 was purposefully designed to improve cognitive impairments. We are working with leading academic researchers to study AKL-T01 as potential treatment for patients with COVID brain fog. Learn About COVID Brain Fog. Megan Ryll April 7, 2021. Discussion with leading academic researchers on COVID brain fog. ENDEAVORRX — AKILI INTERACTIVE EndeavorRx® is the first-and-only FDA cleared prescription treatment for attention in children with ADHD delivered through a digitaltherapy.
PRODUCT DEVELOPMENT
Product Development We take breakthrough science from the lab to patients in the form of effective and captivating digital therapeutics. We uncover groundbreaking neuroscience from around the world and conduct internal discovery to develop new technologies withthe
DISCUSSION WITH LEADING ACADEMIC RESEARCHERS ON COVID Discussion with leading academic researchers on COVID brain fog. Akili is collaborating with Weill Cornell Medicine, NewYork-Presbyterian Hospital and Vanderbilt University Medical Center to study the potential of a digital therapeutic to treat brain fog in COVID-19 survivors. YouTube. Akili Interactive. 47 subscribers. SCIENCE & TECHNOLOGY Explore the science and technology behind our digital treatments. Developed through the collaboration of world-renowned cognitive neuroscientists and acclaimed entertainment and technology designers, Akili has created a proprietary technology platform that represents an entirely new category of medicine. AKILI TECHNOLOGY IMPROVES COGNITIVE IMPAIRMENTS IN ADULTS Primary Endpoint Achieved in Randomized, Controlled Trial of Digital Therapeutic AKL-T03 in Major Depressive Disorder (MDD). Data Presented at the 58 th Annual Meeting of the American College of Neuropsychopharmacology. BOSTON, Mass – December 12, 2019 – Akili Interactive (“Akili” or “Company"), today announced results of its randomized, controlled study of digital therapeutic AKL AKILI ANNOUNCES PUBLICATION OF AKL-T01 ADHD PIVOTAL STUDY First publication of complete results shows improvement across both objective measures of attention and parent and clinician ratings of ADHD symptoms and functional impairments Study results suggest AKL-T01 could play an important role in theJACQUELINE STUDER
Jacqueline Studer. Senior Vice President and General Counsel. Ms. Studer comes to Akili with a 20+ year track record as a senior legal executive building, growing and leading transformative technology companies in highly regulated sectors. Prior to joining Akili, Ms. Studer led the legal, compliance and regulatory organizations asCorporate
WHO WE ARE — AKILI INTERACTIVE All of us at Akili (affectionately known as Akilians), are committed to challenging the status quo of medicine to help people living with cognitive impairment. We are passionate about bringing together top science and entertainment with great user experience to forever change how medicine is designed and delivered. Our Leadership. Featured.PRODUCT DEVELOPMENT
Product Development We take breakthrough science from the lab to patients in the form of effective and captivating digital therapeutics. We uncover groundbreaking neuroscience from around the world and conduct internal discovery to develop new technologies withthe
PUBLICATIONS
Publications. Neurodevelopmental disorders: Attention Deficit/Hyperactivity Disorder (ADHD), Autism Spectrum Disorder (ASD) and Sensory Processing Disorder (SPD) Open label study in children with ADHD, both on and off medications: Published in npj Digital Medicin e on March 26, 2021. Kollins, S.H., Childress, A, Heusser, AC and Lutz, J. (2021).COVID BRAIN FOG
Research Spotlight: COVID Brain Fog More than 100 million people across the globe have been infected with COVID-19. Evidence is mounting on long-term neurological and cognitive symptoms that can persist in some COVID-19 patients, including after the virus is no longer detected in the body.GET ENDEAVOR
Scroll. EndeavorRx® is the first-and-only FDA cleared prescription treatment for attention in children with ADHD delivered through a digital therapy. If you'd like to be informed of updates to EndeavorRx, please fill out the form below. * required field. By submitting this form, you consent to Akili processing your data or personal information JOIN US — AKILI INTERACTIVE Join Us — Akili Interactive. Scroll. Help us change the way medicine is designed, delivered, and experienced. At Akili Interactive, our mission is to ignite new hope for those living with cognitive impairment. We’re bringing together world-class neuroscience with the latest technology and video game entertainment to create a newclass of
SUPPORTERS GALLERY
Ladera Venture Partners (LVP) is a Silicon Valley-based investment firm focused on investments at the convergence of technology and health. LVP is stage-agnostic and highly nimble, focusing on opportunities where the firm's experience, networks and insight can provide meaningful incremental value. Core focus areas include virtualcare, mental
ROB PEREZ — AKILI INTERACTIVE Rob Perez. Executive Chairman & Board Member. Rob Perez is a biopharmaceutical operating executive with more than 25 years of experience in the industry. He is currently the founder and Managing Partner of Vineyard Sound Advisors, LLC as well as the founder and Chairman of Life Science Cares. Previously, he was the Chief ExecutiveOfficer of
EDDIE MARTUCCI
Eddie Martucci, PhD. Co-Founder - Chief Executive Officer. Eddie co-founded Akili Interactive Labs, and as part of PureTech has co-founded two other health-focused start-ups, and helped launch their digital health initiative. He was previously a Kauffman Entrepreneur Fellow, a program sponsored by the Kauffman Foundation of Kansas City,MO
MATTHEW OMERNICK
Matthew Omernick. Co-Founder - Chief Creative Officer. Matt was most recently Executive Art Director at LucasArts, the video game division of Lucasfilm. Matt oversaw studio-wide art teams on multiple projects. Prior to LucasArts, he held Senior positions at Microsoft, Dreamworks, Electronic Arts, and Day 1 Studios. Matt has shipped over 20 game AKILI INTERACTIVEPRODUCTSWHO WE AREJOIN USNEWSCONTACTMATTHEW OMERNICK Akili Interactive is a prescription digital medicine company combining scientific and clinical rigor with the ingenuity of the tech industry to reinvent medicine. PRODUCTS — AKILI INTERACTIVE STARS-Adjunct: Akili data on file, NCT03649074 (manuscript in progress) Of 538 participants using EndeavorRx in clinical studies, 50 participants (9.3%) experienced treatment-related adverse events including frustration, headache, dizziness, emotional reaction, nausea, and aggression. There were no serious adverse events reported. WHO WE ARE — AKILI INTERACTIVE All of us at Akili (affectionately known as Akilians), are committed to challenging the status quo of medicine to help people living with cognitive impairment. We are passionate about bringing together top science and entertainment with great user experience to forever change how medicine is designed and delivered. Our Leadership. Featured.PRODUCT DEVELOPMENT
Product Development We take breakthrough science from the lab to patients in the form of effective and captivating digital therapeutics. We uncover groundbreaking neuroscience from around the world and conduct internal discovery to develop new technologies withthe
ENDEAVORRX — AKILI INTERACTIVE EndeavorRx® is the first-and-only FDA cleared prescription treatment for attention in children with ADHD delivered through a digitaltherapy.
DISCUSSION WITH LEADING ACADEMIC RESEARCHERS ON COVID Discussion with leading academic researchers on COVID brain fog. Akili is collaborating with Weill Cornell Medicine, NewYork-Presbyterian Hospital and Vanderbilt University Medical Center to study the potential of a digital therapeutic to treat brain fog in COVID-19 survivors. YouTube. Akili Interactive. 47 subscribers.GET ENDEAVOR
Scroll. EndeavorRx™ is the first-and-only FDA cleared prescription treatment for attention in children with ADHD delivered through a digital therapy. If you'd like to be informed of updates to EndeavorRx, please fill out the form below. * required field. By submitting this form, you consent to AKILI TECHNOLOGY IMPROVES COGNITIVE IMPAIRMENTS IN ADULTS Primary Endpoint Achieved in Randomized, Controlled Trial of Digital Therapeutic AKL-T03 in Major Depressive Disorder (MDD). Data Presented at the 58 th Annual Meeting of the American College of Neuropsychopharmacology. BOSTON, Mass – December 12, 2019 – Akili Interactive (“Akili” or “Company"), today announced results of its randomized, controlled study of digital therapeutic AKLJACQUELINE STUDER
Jacqueline Studer. Senior Vice President and General Counsel. Ms. Studer comes to Akili with a 20+ year track record as a senior legal executive building, growing and leading transformative technology companies in highly regulated sectors. Prior to joining Akili, Ms. Studer led the legal, compliance and regulatory organizations asCorporate
EDDIE MARTUCCI
Eddie Martucci, PhD. Co-Founder - Chief Executive Officer. Eddie co-founded Akili Interactive Labs, and as part of PureTech has co-founded two other health-focused start-ups, and helped launch their digital health initiative. He was previously a Kauffman Entrepreneur Fellow, a program sponsored by the Kauffman Foundation of Kansas City,MO
AKILI INTERACTIVEPRODUCTSWHO WE AREJOIN USNEWSCONTACTMATTHEW OMERNICK Akili Interactive is a prescription digital medicine company combining scientific and clinical rigor with the ingenuity of the tech industry to reinvent medicine. PRODUCTS — AKILI INTERACTIVE STARS-Adjunct: Akili data on file, NCT03649074 (manuscript in progress) Of 538 participants using EndeavorRx in clinical studies, 50 participants (9.3%) experienced treatment-related adverse events including frustration, headache, dizziness, emotional reaction, nausea, and aggression. There were no serious adverse events reported. WHO WE ARE — AKILI INTERACTIVE All of us at Akili (affectionately known as Akilians), are committed to challenging the status quo of medicine to help people living with cognitive impairment. We are passionate about bringing together top science and entertainment with great user experience to forever change how medicine is designed and delivered. Our Leadership. Featured.PRODUCT DEVELOPMENT
Product Development We take breakthrough science from the lab to patients in the form of effective and captivating digital therapeutics. We uncover groundbreaking neuroscience from around the world and conduct internal discovery to develop new technologies withthe
ENDEAVORRX — AKILI INTERACTIVE EndeavorRx® is the first-and-only FDA cleared prescription treatment for attention in children with ADHD delivered through a digitaltherapy.
DISCUSSION WITH LEADING ACADEMIC RESEARCHERS ON COVID Discussion with leading academic researchers on COVID brain fog. Akili is collaborating with Weill Cornell Medicine, NewYork-Presbyterian Hospital and Vanderbilt University Medical Center to study the potential of a digital therapeutic to treat brain fog in COVID-19 survivors. YouTube. Akili Interactive. 47 subscribers.GET ENDEAVOR
Scroll. EndeavorRx™ is the first-and-only FDA cleared prescription treatment for attention in children with ADHD delivered through a digital therapy. If you'd like to be informed of updates to EndeavorRx, please fill out the form below. * required field. By submitting this form, you consent to AKILI TECHNOLOGY IMPROVES COGNITIVE IMPAIRMENTS IN ADULTS Primary Endpoint Achieved in Randomized, Controlled Trial of Digital Therapeutic AKL-T03 in Major Depressive Disorder (MDD). Data Presented at the 58 th Annual Meeting of the American College of Neuropsychopharmacology. BOSTON, Mass – December 12, 2019 – Akili Interactive (“Akili” or “Company"), today announced results of its randomized, controlled study of digital therapeutic AKLJACQUELINE STUDER
Jacqueline Studer. Senior Vice President and General Counsel. Ms. Studer comes to Akili with a 20+ year track record as a senior legal executive building, growing and leading transformative technology companies in highly regulated sectors. Prior to joining Akili, Ms. Studer led the legal, compliance and regulatory organizations asCorporate
EDDIE MARTUCCI
Eddie Martucci, PhD. Co-Founder - Chief Executive Officer. Eddie co-founded Akili Interactive Labs, and as part of PureTech has co-founded two other health-focused start-ups, and helped launch their digital health initiative. He was previously a Kauffman Entrepreneur Fellow, a program sponsored by the Kauffman Foundation of Kansas City,MO
PRODUCTS — AKILI INTERACTIVE STARS-Adjunct: Akili data on file, NCT03649074 (manuscript in progress) Of 538 participants using EndeavorRx in clinical studies, 50 participants (9.3%) experienced treatment-related adverse events including frustration, headache, dizziness, emotional reaction, nausea, and aggression. There were no serious adverse events reported. NEWS — AKILI INTERACTIVE Explore the latest news from Akili. For press inquiries, please contact pr@akiliinteractive.com. Featured. Apr 7, 2021. Akili Collaborates with Weill Cornell Medicine, NewYork-Presbyterian Hospital and Vanderbilt University Medical Center to Study Digital Therapeutic AKL-T01 as Treatment for COVID Brain Fog. Apr 7, 2021. Read More →. Apr 7, 2021.PUBLICATIONS
Publications. Neurodevelopmental disorders: Attention Deficit/Hyperactivity Disorder (ADHD), Autism Spectrum Disorder (ASD) and Sensory Processing Disorder (SPD) Open label study in children with ADHD, both on and off medications: Published in npj Digital Medicin e on March 26, 2021. Kollins, S.H., Childress, A, Heusser, AC and Lutz, J. (2021).COVID BRAIN FOG
Akili digital therapeutic AKL-T01 was purposefully designed to improve cognitive impairments. We are working with leading academic researchers to study AKL-T01 as potential treatment for patients with COVID brain fog. Learn About COVID Brain Fog. Megan Ryll April 7, 2021. Discussion with leading academic researchers on COVID brain fog. SCIENCE & TECHNOLOGY Explore the science and technology behind our digital treatments. Developed through the collaboration of world-renowned cognitive neuroscientists and acclaimed entertainment and technology designers, Akili has created a proprietary technology platform that represents an entirely new category of medicine.SUPPORTERS GALLERY
Ladera Venture Partners (LVP) is a Silicon Valley-based investment firm focused on investments at the convergence of technology and health. LVP is stage-agnostic and highly nimble, focusing on opportunities where the firm's experience, networks and insight CONTACT — AKILI INTERACTIVE Boston Office. 125 Broad Street. 5th Floor. Boston, MA 02110. SF Bay Area Office. 125 E Sir Francis Drake Blvd. Suite 300. Larkspur, CA94939.
ROB PEREZ — AKILI INTERACTIVE Rob Perez. Executive Chairman & Board Member. Rob Perez is a biopharmaceutical operating executive with more than 25 years of experience in the industry. He is currently the founder and Managing Partner of Vineyard Sound Advisors, LLC as well as the founder and Chairman of Life Science Cares. Previously, he was the Chief ExecutiveOfficer of
ANIL JINA — AKILI INTERACTIVE Anil Jina. Chief Medical Officer. Dr. Jina studied medicine in Ireland at RCSI (the Royal College of Surgeons in Ireland) and worked as a hospital physician in the Irish healthcare system until he joined the biopharmaceutical industry in 2001. He has worked with Pfizer (CNS Medical Adviser, UK/Ireland and Global Medical Director, PsychiatryCARL GOTTLIEB
Carl Gottlieb. Senior Vice President Engineering. Carl is a proven technology leader with over 20 years of experience shaping engineering and product organizations. Starting off as a full stack engineer in manufacturing, he went on to develop technical expertise in modern web and mobile development. Prior to Akili, Carl held senior leadership Science & Tech Products Who We Are Join UsNews Contact __
__
Back Overview Product Development COVID Brain Fog Publications Science & Tech Overview Product Development COVID Brain Fog Publications Products Who We Are Join Us News Contact__ __
Scroll
ENDEAVORRX®, THE FIRST-AND-ONLY PRESCRIPTION TREATMENT DELIVERED THROUGH A VIDEO GAME WE’RE EXCITED TO ANNOUNCE THAT ENDEAVORRX IS NOW FDA CLEARED. BE THE FIRST TO EXPERIENCE THE FUTURE OF MEDICINE. VISIT ENDEAVORRX.COM.
It's time to play your medicine. It's time to change the way medicine is designed, delivered and experienced. At Akili, we believe effective medicine for serious illnesses can also be fun and engaging. We're creating a new class of digital medicines for people living with cognitive impairment, delivered through captivating video game experiences. Are you ready to play your medicine?Learn more
RESEARCH SPOTLIGHT
COVID BRAIN FOG
Evidence is mounting on long-term cognitive impairments in some COVID-19 survivors. We’re working with leading academic research institutions to study the potential of our technology in COVID brain fog. Learn more about COVID brain fog and our clinical studies.Our latest research
\n","url":"https://akiliinteractive.wistia.com/medias/6pjigiu5nu","width":960,"height":540,"providerName":"Wistia, Inc.","thumbnailUrl":"https://embed-ssl.wistia.com/deliveries/e6a8d8efb437a6875497c7587baf115e.jpg?image_crop_resized=960x540","resolvedBy":"wistia"}" data-block-type="32" id="block-yui_3_17_2_1_1570033353901_21650"> " data-provider-name="Wistia, Inc." id="yui_3_17_2_1_1622902611042_153"> IMAGINE WHAT MEDICINE CAN BE® We’re bringing together world-class neuroscience with the latest technology and video game entertainment to challenge the status quo of medicine. Our digital medicine is not delivered through a pill or syringe, but rather through a proprietary and captivating video gameexperience.
Effective medicine that you can enjoy taking – now that’srefreshing.
LATEST PRESS RELEASES Akili Media Center ArchiveMay 26, 2021
Akili Secures $160 Million in Financing; Poised to Deliver on the Promise of Digital TherapeuticsMay 26, 2021
Read More →
May 26, 2021
Apr 7, 2021
Akili Collaborates with Weill Cornell Medicine, NewYork-Presbyterian Hospital and Vanderbilt University Medical Center to Study Digital Therapeutic AKL-T01 as Treatment for COVID Brain FogApr 7, 2021
Read More →
Apr 7, 2021
Oct 21, 2020
Researchers Present New Outcome Data for Akili Digital Therapeutic EndeavorRx™ in Pediatric ADHDOct 21, 2020
Read More →
Oct 21, 2020
Oct 7, 2020
Akili Announces Appointment of Chief Marketing OfficerOct 7, 2020
Read More →
Oct 7, 2020
SEE MORE Group 2
Home Endeavor SectionHome Banner Section
Home C19 Brainfog SectionHome Video Section
Home Leadership Section Logo/AStamp/Registered/White Home Science & Tech Who We Are News Join Us Contact Copyright © 2020 Akili Interactive Labs, Inc. All rights reserved. Terms of Use | Privacy PolicyDetails
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0